Woodstock Corp Sells 505 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Woodstock Corp decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,655 shares of the biopharmaceutical company's stock after selling 505 shares during the quarter. Woodstock Corp's holdings in Regeneron Pharmaceuticals were worth $3,316,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Rakuten Securities Inc. lifted its stake in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 19 shares in the last quarter. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $26,000. Fairfield Financial Advisors LTD purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $37,000. Truvestments Capital LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter worth approximately $39,000. Finally, Itau Unibanco Holding S.A. purchased a new position in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $42,000. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

REGN traded down $11.65 on Friday, hitting $681.58. The company had a trading volume of 1,107,622 shares, compared to its average volume of 678,713. The stock has a market cap of $74.90 billion, a price-to-earnings ratio of 16.87, a price-to-earnings-growth ratio of 1.60 and a beta of 0.10. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.28 and a quick ratio of 4.46. The company's fifty day moving average price is $741.54 and its 200 day moving average price is $952.59. Regeneron Pharmaceuticals, Inc. has a 1-year low of $666.25 and a 1-year high of $1,211.20.

Analysts Set New Price Targets

REGN has been the subject of a number of research analyst reports. Morgan Stanley reduced their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a report on Friday, November 1st. Cantor Fitzgerald reissued a "neutral" rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Bank of America reaffirmed an "underperform" rating and set a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Wells Fargo & Company dropped their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating on the stock in a report on Friday, January 10th. Finally, Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating for the company in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $1,015.38.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.